ArticleCancer biology & medicine2019
Interpretation of breast cancer screening guideline for Chinese women.
Article in Cancer biology & medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 3 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- Clinical guidelines for the management of mammographic density: a systematic review of breast screening guidelines worldwide.JNCI cancer spectrum · 2024Pooled it
- A systematic review of recommendations on screening strategies for breast cancer due to hereditary predisposition: Who, When, and How?Cancer medicine · 2021Pooled it
- Pathologic Complete Response and Its Impact on Breast Cancer Recurrence and Patient's Survival after Neoadjuvant Therapy: A Comprehensive Meta-Analysis.Computational and mathematical methods in medicine · 2021Pooled it
- Prediction of total hospital expenses of patients undergoing breast cancer surgery in Shanghai, China by comparing three models.BMC health services research · 2021Trial
- Optimising screening intervals and BI-RADS management pathways in ultrasound-based breast cancer screening: real-world evidence from Shenzhen (2018-2023).Breast cancer research and treatment · 2026Article
- Breast Cancer Screening Programs in China: Implementation, Challenges, and Future Perspectives.Korean journal of radiology · 2026Review
- Epidemiology, early detection, and management of breast cancer in China: A comprehensive review.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025Article
- Knowledge, attitude, and practice among non-breast cancer women towards breast cancer screening with a focus on economic factors.Scientific reports · 2025Article
- Global, regional, and national burden of breast cancer in young women from 1990 to 2021: findings from the global burden of disease study 2021.BMC cancer · 2025Article
- Article
- A novel model based on lipid metabolism-related genes associated with immune microenvironment predicts metastasis of breast cancer.Discover oncology · 2024Article
- Knowledge, attitude, and practice toward ultrasound screening for breast cancer among women.Frontiers in public health · 2024Article
- Breast cancer: Epidemiology, risk factors and screening.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2023Article
- An effective convolutional neural network for classification of benign and malignant breast and thyroid tumors from ultrasound images.Physical and engineering sciences in medicine · 2023Article
- Epidemiology and clinicopathologic features of breast cancer in China and the United States.Translational cancer research · 2023Article
- Ultrasound for Breast Cancer Screening in Resource-Limited Settings: Current Practice and Future Directions.Cancers · 2023Review
- Correlation of androgen receptor with ultrasound, clinicopathological features and clinical outcomes in breast cancer.Insights into imaging · 2023Article
- Cost-effectiveness evaluation of risk-based breast cancer screening in Urban Hebei Province.Scientific reports · 2023Article
- Identification of Three Circulating MicroRNAs in Plasma as Clinical Biomarkers for Breast Cancer Detection.Journal of clinical medicine · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is the most common malignant tumor in Chinese women. Early screening is the best way to improve the rates of early diagnosis and survival of breast cancer patients. The peak onset age for breast cancer in Chinese women is considerably younger than those in European and American women. It is imperative to develop breast cancer screening guideline that is suitable for Chinese women. By summarizing the current evidence on breast cancer screening in Chinese women, and referring to the latest guidelines and consensus on breast cancer screening in Europe, the United States, and East Asia, the China Anti-Cancer Association and National Clinical Research Center for Cancer (Tianjin Medical University Cancer Institute and Hospital) have formulated population-based guideline for breast cancer screening in Chinese women. The guideline provides recommendations on breast cancer screening for Chinese women at average or high risk of breast cancer according to the following three aspects: age of screening, screening methods, and screening interval. This article provides more detailed information to support the recommendations in this guideline and to provide more direction for current breast cancer screening practices in China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.